Loading organizations...
§ Private Profile · Chicago, IL, USA
Biotech company developing synthetic proteins using generative AI and machine learning for therapeutics, focused on immune-mediated diseases.
Based in Chicago, Illinois, Evozyne is a biotechnology company that utilizes generative artificial intelligence and machine learning to design and develop novel synthetic proteins for therapeutic and sustainability applications. The organization focuses primarily on treating immune-mediated diseases by leveraging its proprietary EvoGen AI platform for protein design and its EvoLab facility for high-throughput testing. The enterprise operates with a workforce of an estimated 50 to 200 employees and generates revenue potential through strategic research collaborations and licensing agreements with major pharmaceutical corporations such as Takeda. Evozyne has raised significant capital to advance its clinical pipeline, highlighted by an $81 million Series B funding round backed by prominent institutional investors including OrbiMed, Fidelity Management & Research Company, Paragon Biosciences, and NVIDIA. The biotechnology company was founded in 2020 by Jeffrey Aronin, Rama Ranganathan, and Mike Gamson.
Evozyne has raised $81.0M across 1 funding round.
Evozyne has raised $81.0M in total across 1 funding round.
Evozyne is a Chicago-based biotechnology company that designs novel protein therapeutics using generative AI, machine learning, and evolutionary principles to address unmet medical needs and broader challenges in therapeutics and sustainability.[1][2][3][5] The company engineers synthetic proteins—termed "Natural Machines"—that perform functions previously thought impossible, such as improving drug discovery speed, reducing costs, and enabling applications in biopharmaceuticals, agriculture, and environmental solutions like carbon conversion and bio-based batteries.[2][3][4] Evozyne serves patients with serious diseases, agricultural sectors for crop yields, and industries tackling climate change, solving problems like unaddressable patient needs through iterative design/build/test cycles that boost success probability.[1][2][5] With 50-200 employees, $10-100M in funding, and a new 30,000 sq. ft. lab in Lincoln Park, the company shows strong growth momentum, attracting top talent and expanding amid rising demand for AI-driven protein engineering.[2][3][4]
Founded in 2019 by Paragon Biosciences, Evozyne emerged as a data-driven molecular engineering venture in Chicago, combining computational modeling, AI, machine learning, and natural evolutionary principles to create synthetic proteins with unprecedented precision.[2][3] Some sources list a 2020 or 2022 founding, but the consistent narrative ties it to Paragon's 2019 launch, with early traction from a peer-reviewed Science publication validating its evolution-based enzyme engineering process.[2][3][4] Pivotal moments include rapid commercial demand prompting a high-tech wet lab buildout completed around 2021, positioning Evozyne in Chicago's growing life science hub and enabling plans to add hundreds of jobs.[2][4]
Evozyne rides the explosive trend of AI-driven drug discovery and synthetic biology, where generative models extrapolate from nature's evolutionary designs to unlock novel proteins at scales impossible before, amid surging demand for precision therapeutics and climate solutions.[1][2][3][5] Timing is ideal as biotech hubs like Chicago expand, fueled by investors like Paragon Biosciences, while market forces—rising healthcare costs, drug development failures (90%+ attrition), and global sustainability mandates—favor Evozyne's cost-reducing, high-success approach.[2][4] The company influences the ecosystem by advancing protein engineering benchmarks, as seen in its Science publication, inspiring AI-bio convergence and positioning Chicago as a life sciences powerhouse.[2]
Evozyne is poised to advance multiple protein therapeutics into clinical stages, leveraging its AI platform for faster iterations and expansions into sustainability applications like clean energy enzymes.[1][2][5] Trends in multimodal AI, larger protein datasets, and regulatory nods for AI-designed drugs will accelerate its trajectory, potentially capturing biopharma partnerships amid a $100B+ protein therapeutics market.[3] Its influence may evolve from pioneer to platform leader, powering ecosystem-wide breakthroughs in human health and planetary challenges, fulfilling its mission to engineer proteins that reshape what's possible.[1][4][5]
Evozyne has raised $81.0M across 1 funding round. Most recently, it raised $81.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $81M Series B | OrbiMed, Fidelity Management & Research Company | 1955 Capital, Founders Fund, Lightspeed Venture Partners, Sequoia Capital, Sofinnova Investments, TED Driscoll, NVentures, Paragon Biosciences, Valor Equity Partners | Announced |
Evozyne has raised $81.0M in total across 1 funding round.
Evozyne's investors include OrbiMed, Fidelity Management & Research Company, 1955 Capital, Founders Fund, Lightspeed Venture Partners, Sequoia Capital, Sofinnova Investments, Ted Driscoll, NVentures, Paragon Biosciences, Valor Equity Partners.